ered from CSF, indicating that the binding protein acted to retain T 4 in CSF. However, 125 I-labeled T4 uptake into the ependymal region (ER) of the frontal cortex also increased by 13 times compared with control conditions. Elevation was also seen in the hippocampus (HC) and brain stem. Uptake was significantly inhibited by the presence of endocytosis inhibitors nocodazole and monensin by Ͼ 50%. These data suggest that the distribution of T 4 from CSF into brain and CP is carrier mediated, TTR dependent, and via RME. These results support a role for TTR in the distribution of T 4 from CSF into brain sites around the ventricular system, indicating those areas involved in neurogenesis (ER and HC). hippocampus; ependymal region; blood-brain barrier THE BRAIN IS ONE OF THE MAIN target organs for thyroid hormones (TH). TH have marked effects on the central nervous system (CNS), particularly during the developmental period (10) and for neuronal regeneration in adults after injury (32) . Thyroxine (T 4 ) is synthesized outside the brain by the thyroid glands and released into the blood where it binds to a number of proteins, such as albumin (ALB), transthyretin (TTR), and thyroidbinding globulin (TBG) (21) . Theoretically, the three proteins form a "buffering" system for free/bound T 4 between the concentration of free T 4 in human serum (ϳ30 pM) and the solubility limit for T 4 (ϳ2 M) (27) .
In the cerebrospinal fluid (CSF), the main binding proteins are TTR and ALB, but in lower concentrations compared with plasma. Free T 4 concentration in CSF is 70 pM in dogs (16) , and the total T 4 in humans is ϳ644 pM (0.5 ng/ml) (33) , and the levels depend on CSF proteins. However, the specific role of some T 4 -binding proteins in the CSF, such as TTR, which is secreted by the choroid plexuses (CP) remains controversial.
It has been suggested that TTR assists T 4 transport from blood to brain across the blood-CSF barrier (BCSFB) (8, 28) , and therefore TTR synthesis is critical to the supply of CNS T 4 . However, research using the TTR null mouse (26) has shown that lack of TTR has little effect on brain T 4 , despite low CSF levels, thus rejecting a role for TTR in control of T 4 entry to the brain.
Once in the CSF, T 4 can be accumulated by the CP, as it has been shown in in vitro studies of isolated choroid plexus (8) , as well as in in vivo ventriculocisternal (V-C) perfusion studies (18) . In addition, T 4 may be lost by drainage with CSF from the ventricle or efflux to blood across the BCSFB and blood-brain barrier (BBB).
Little is known about what happens to T 4 once it enters the CSF or the role of TTR in its distribution. This study aimed to investigate whether CSF-borne T 4 was subsequently taken up by the brain and the role of TTR in this process, by using the rabbit in vivo V-C perfusion technique.
MATERIALS AND METHODS

V-C Perfusion
All procedures were within the current guidelines of the Animals (Scientific Procedures) Act, 1986, United Kingdom. This technique is based on the method previously described (7) . New Zealand White rabbits of either sex weighing 1.5-4 kg were anesthetized by intravenous injection with a mixture of medetomidine hydrochloride (Domitor) 0.5 mg/kg and pentobarbital sodium (Sagatal) 10 mg/kg.
A catheter inflow needle was placed in each lateral ventricle as described (7) . A single outflow needle was positioned in the cisterna magna. Artificial CSF (aCSF) was infused into the ventricles at a total rate of 60 l/min, containing 125 I-labeled T4 (0.37 MBq/40 ml) and the extracellular marker 14 Blue dextran is a large marker molecule (mol wt 2 ϫ 10 6 ) (Sigma), confined to the CSF and was used to determine the secretion rate (K f) of the newly synthesized CSF (7). K f (l/min) ϭ (Cin Ϫ Cout/Cout) ϫ P, where P is the rate of perfusion (l/min) and C in and Cout are the concentration of the blue dextran (arbitrary units) entering and leaving the ventricles measured on a Unicam (UV-1) spectrophotometer with absorbance at 625 nm.
Sampling of Brain Tissue
At the end of the perfusion time, the animal was humanely killed by anesthesia overdose and the brain was rapidly removed. The ventricles were then opened and rinsed with 0.9% saline. The lateral and fourth ventricle CPs were removed, and the ventricular ependymal region (ER) in the frontal cortex region was dissected. The tissue containing the ependymal layer in contact with CSF, was dissected as a 1.0-mm-thick layer from the area next to the midline (septal side, see Ref. 6) , covering the midbrain toward the floor of the lateral ventricle. A scalpel was used horizontally to gently tease and peel back the white ER from the ventricular wall. Any gross contamination with brain parenchyma, especially gray matter, could be clearly seen postisolation. For these purposes, the samples were not further microdissected to avoid all contamination with underlying cells; however, T 4 uptake in this tissue was compared with samples of tissue immediately below the dissected region (again, 1-mm thick) designated the sub-ER (SER). The brain was separated into different sections of frontal cortex, hippocampus (HC), cerebellum, brain stem (BS), caudate nucleus, and ependyma, and the remaining brain sections were also homogenized by using a brain homogenizer. CSF inflow and outflow samples (100 l in triplicate), and tissue samples were solubilized for 48 h in 0.5 ml Solusol (National Diagnostic) in liquid scintillation vials, and 3.5 ml of scintillation liquid added (Ultima Gold, Packard, UK). Samples were counted (LKB Wallac 1219 Beta liquid scintillation counter), and the 14 C-mannitol and 125 I-labeled T4 activities expressed as dpm (disintegrations per minute).
Preparation of TTR
One milligram of human TTR (Biodesign International) was dissolved in 10 ml of sterile saline and kept frozen at Ϫ25°C until needed. The complex was prepared by adding 100 l 125 I-labeled T4 (18.58 pmol) and 1 ml TTR (0.1 mg/ml) to 0.5 ml saline, and allowed to bind for 20 min at room temperature. The solution was dialyzed overnight at 4°C in seamless cellulose tubing (with a cutoff of 12,000 mol wt) with 16-mm diameter, to remove any unbound 125 I. One milliliter of this solution was then added to 40 ml aCSF to give final concentration of 0.28 nM T4 and 1.52 g/ml TTR.
Application of Drugs
Endocytosis inhibitors were included in the TTR-125 I-labeled T4 complex experiments for 2 h continuously, and these were nocodazole (50 M) or monensin (100 M). In separate experiments, unlabeled-T 4 (100 M, 200 M) was also used.
Expression of Results
Brain uptake. At the end of 2-h V-C perfusion, the regional brain uptake (R Br) of 125 I-labeled T4 was expressed as RBr (ml/g) ϭ 100ϫ tissue (dpm/g)/Cin (dpm/ml), where Cin is the radioactivity per unit volume of entering perfusion fluid (aCSF).
The net cellular uptake was calculated after correction for 14 Cmannitol uptake.
I-Labeled T4 Recovery in CSF
The 125 I remaining in outflow CSF in each 10-min sample was measured. The %recovery for each sample was calculated from (C out/Cin) ϫ 100.
The steady-state ratio of 125 I-labeled T4 in recovered aCSF was calculated from the mean value of %recovery derived from the last four samples of perfusion fluid.
Materials
Unless stated, all consumables were purchased from Sigma.
Statistics
Values are means Ϯ SE, and comparisons between test and controls were calculated using unpaired Student's t-test. Values of P Ͻ 0.05 were considered to be significant.
RESULTS
CSF Recovery of 125 I-labeled T 4 after 4-h V-C Perfusion
Mean curves describing the achievement of steady state during V-C perfusion with aCSF containing 125 I-labeled T 4 and blue dextran are shown (Fig. 1) . The steady-state 125 I-labeled T 4 recovery reached 46.6 Ϯ 4.9% after 2 h, and the average value for 4 h was 46.1 Ϯ 4.3% (n ϭ 9). Blue dextran recovery was 81.1 Ϯ 3.6% indicating de novo synthesis of CSF, which was calculated as 12.1 Ϯ 1.3 l/min. Figure 1 also shows that after 3.5-h perfusion, blue dextran recovery increased, indicating reduced CSF secretion, so affecting 125 I-labeled T 4 recovery. Therefore, subsequent experiments were conducted for 2 h.
Brain and CP Uptake
To investigate whether 125 I-labeled T 4 movement from aCSF to brain is carrier mediated, uptake was examined in the presence of different concentrations of unlabeled-T 4 added to the aCSF.
The uptake of 125 I-labeled T 4 into whole brain tissue that had been homogenized (Fig. 2 ) was significantly reduced (P Ͻ 0.05) in presence of 200 M unlabeled-T 4 . In addition, uptake of 125 I-labeled T 4 into the lateral ventricle choroid plexus (Fig.  3) was reduced by more than 65% in presence of both concentrations, indicating a saturable carrier-mediated process.
In these experiments, the mean CSF %recovery of 125 Ilabeled T 4 , increased (Table 1) in the presence of both 100 and 200 M unlabeled-T 4 , consistent with reduced uptake into in vivo homogenized brain tissues and CP.
Effect of TTR on T 4 Recovery from CSF
To investigate whether 125 I-labeled T 4 movement from aCSF into brain is affected by TTR, TTR-125 I-labeled T 4 complex was added to the perfusion fluid during a 2-h V-C perfusion at a final concentration of 1.52 g/ml TTR. The %recovery of 125 I-labeled T 4 was significantly increased from 41.1 Ϯ 3.4 to 75.3 Ϯ 7.0% (P Ͻ 0.01), with a 79% change ( Fig. 4 ; Table 2 ).
Uptake Into Brain Regions Is Increased With TTR
T 4 uptake into ependymal and SERs. Under control condition uptake of 125 I-labeled T 4 into the ER of the frontal cortex (0.04 Ϯ 0.01 ml/g) was found to be significantly higher than the SER (0.01 Ϯ 0.001 ml/g; P Ͻ 0.01, Fig. 5 ). In the presence of TTR, this uptake was significantly increased to 0.57 Ϯ 0.13 ml/g (P Ͻ 0.01) and 0.24 Ϯ 0.07 ml/g (P Ͻ 0.05), respectively (Fig. 5) .
Uptake into HC, BS, and CP. Uptake into the HC without ER (HC with no ER), was also significantly increased from 0.02 Ϯ 0.01 to 0.19 Ϯ 0.05 ml/g, (P Ͻ 0.01; Fig. 5D ). When T 4 uptake was measured in the HC, including the ER (HC with ER), TTR resulted in a very large increase from 0.034 Ϯ 0.01 ml/g to 0.64 Ϯ 0.21 ml/g, (P Ͻ 0.01; Fig. 5C ).
TTR caused a marked increase in the uptake of 125 I-labeled T 4 into BS by Ͼ50 times compared with control (Fig. 5E ). Under control conditions the highest uptake of 125 I-labeled T 4 in the brain was found in the CPs, and this was significantly increased by greater than two times in the presence of TTR-125 I-labeled T 4 complex (Fig. 5F ).
Effect of Endocytosis Inhibitors on T 4 Recovery and Brain Uptake
The uptake of TTR-125 I-labeled T 4 complex was investigated in presence of either receptor-mediated endocytosis (RME) inhibitors, nocodazole, and monensin. Neither affected the %recovery of T 4 in aCSF; however, both affected brain tissue uptake. Nocodazole reduced uptake into ER and SER by Ͼ80% (Fig. 5B) . Monensin produced similar results, effectively negating the effect of TTR. The data strongly indicate that TTR-125 I-labeled-T 4 uptake involves an endocytotic process.
Uptake into HC, BS, and CP. With nocodazole, there was a marked inhibition in T 4 uptake into the HC and BS, (Fig. 5 , C-E), consistent with that found in the ER and SER of the frontal cortex.
In the CP, monensin reduced TTR-125 I-labeled T 4 uptake significantly; however, nocodazole had no significant effect (Fig. 5F ).
DISCUSSION
The present study has shown that T 4 is taken up from CSF into CP and various brain regions. This uptake is partially carrier mediated, enhanced in the presence of TTR, and likely to involve RME.
The finding that T 4 entry from CSF into brain is via a carrier-mediated process, is consistent with previous studies with CP (8) . From the current study, the data indicate that this process favors a transport mechanism for T 4 in the direction from CSF across CP to the blood. Early observations support this suggestion since in mice, transport of T 4 from brain toward the blood is saturable (1). In addition, various CNS cells show saturable TH uptake including human glioma (15) , rat glia (12) , and astrocytes (2).
TTR Role in T 4 Transport From CSF Into CP and Brain Tissues
Over the last decade, there has been a debate about the role of TTR in T 4 transport, focusing primarily on uptake from plasma to CNS (25) (26) (27) (28) and whether TTR is essential for this process at either BBB or BCSFB. The present data confirm a role for TTR in T 4 distribution once the hormone has entered the CSF. This study suggests that binding of TTR to T 4 in the CSF compartment prevents T 4 removal from CSF. It is not easy to identify in vivo the exact removal pathway, but both BBBs and BCSFBs could be involved. Indeed, a recent study from our laboratory (5) showed that TTR reduced T 4 transport from CSF to blood across the isolated perfused sheep CP. The availability of TTR in CSF is also correlated with increased T 4 uptake into CP and brain. The reason for elevated tissue uptake may be a simple consequence of elevated T 4 in CSF, providing a concentration gradient favoring tissue uptake. Additionally, we have evidence for RME of TTR/T 4 since RME inhibitors reduced uptake. RME of TTR/T 4 would be favored in a high TTR environment and allow more T 4 uptake than by diffusion alone.
TTR-dependent T 4 uptake in ependyma is consistent with previous studies showing TTR endocytosis by ependyma (20) , suggesting that the presence of TTR results in a uniform distribution of T 4 within the brain parenchyma similar to the effect in perfused liver lobules (23) . After exchange between the CSF and extracellular fluid, free T 4 within the extracellular Values are means Ϯ SE; n is the number of experiments. *P Ͻ 0.05, significant difference from complex, †P Ͻ 0.01, significant difference from control. Fig. 5 . The uptake of 125 I-labeled T4 into the ependyma region (ER) of the frontal cortex (A), sub-ER (SER, n ϭ 6) (B), hippocampus including ER (HC with ER, n ϭ 6) (C), HC excluding ER (HC with no ER, n ϭ 6) (D), brain stem (BS) (n ϭ 6) (E), and choroid plexus (CP, n ϭ 9) (F) after 2-h V-C perfusion. The uptake of 125 I-labeled T4 was measured under control condition, in the presence of 1.52 g/ml TTR as TTR-125 I-labeled T4 complex, n ϭ 5, (ϩTTR), and with either of two endocytosis inhibitors, 50 M nocodazole (TTRϩN, n ϭ 3) and 100 M monensin (TTRϩM, n ϭ 3). Values are means Ϯ SE, *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001, difference from ϩTTR, †, † † difference from control P Ͻ 0.01, P Ͻ 0.05, respectively. space could be subject to rapid uptake by cells, and conversion to T 3 by type II deiodinase (29) . Elevated T 4 uptake in the presence of TTR suggests that the even distribution of T 4 within this tissue is not only dependent on the free fraction of T 4 in CSF, but also on the T 4 bound to TTR.
Ependyma as Reservoir for Brain Uptake of T 4
To reach its targets within the brain, T 4 from CSF must first cross the ER of the ventricles. The ER is a gateway between CSF and brain, and it appears that TTR mediates transfer of T 4 from CSF and facilitates uptake into the ER, to a greater extent than into the SER. Increased ER uptake of T 4 is likely to involve both passive diffusion of T 4 and a TTR-T 4 receptor, allowing for greater uptake than can be achieved by diffusion alone, similar to that found in human ependymoma cells (19, 20) . The ER could, therefore, act as a reservoir for brain T 4 , relevant under conditions of increased hormone demand by various regions. Previous studies have demonstrated receptormediated uptake and internalization of TTR in cultured human astrocytoma cells (9) . The HC also accumulated T 4 in the presence of TTR. Interestingly, TTR is abundantly expressed in BS, HC, and cerebral cortex (4, 22) , as well as CP (8) , which may act to enhance T 4 uptake and retention by cells. Since THs may facilitate neuronal regeneration after CNS injury (32) , it is interesting that the ER, which had high TTR 125 I-labeled T 4 uptake in this study, is also an area of active neurogenesis in the adult, which increases after brain injury (24) .
RME
The inhibitory effect of the endocytosis inhibitor monensin on the CP, ER, SER, and HC uptake of TTR-125 I-labeled T 4 , suggests the presence of RME, as discussed above. Monensin blocks protein degradation and trafficking out of the endosome (13) , but the drug's effect on the intracellular organelle was not investigated in our study. The effect also appeared to be similar to that obtained in in vitro studies in which these drugs reduced the uptake of T 4 in cultured anterior pituitary cells by 40% (11) . It should be noted that monensin also acts as a sodium ionophore that rapidly exchanges Na and H ions (31) , and so it is likely that Na/H exchange is increased in brain tissues in our study. From the work of others on the kidney (14) , a link between Na/H exchange (via NHE3) and receptor-mediated endocytosis has been made, in which the presence of Na/H exchange is essential for RME. We did not study Na/H exchange directly; however, from previous work we would presume that any elevation of Na/H exchange induced by monensin would encourage uptake by RME. In contrast, we saw inhibition of T 4 uptake, which suggests that the effect of monensin on T 4 /TTR uptake is as an RME inhibitor, although changes in intracellular pH as a regulatory mechanism cannot be ruled out, and warrant further investigation.
Early findings (17) established that both drugs, monensin and nocodazole, inhibited endocytosis of ALB by the alveolar epithelium in rabbit. Because it is known as a microtubule toxin (3), nocodazole may cause disruption to the endosomal recycling of transporter proteins, and therefore it can be proposed that the TTR-125 I-labeled-T 4 complex cycles between the cell surface and intracellular stores by a nocodazolesensitive mechanism in the brain tissue and to a lesser extent in the CP.
Despite inhibition of tissue uptake by RME inhibitors, recovery of T 4 in CSF did not increase. This is perhaps not surprising, given the very large pool of T 4 in bulk CSF relative to the potential small pool in the tissue surrounding the ventricles.
The data presented in the current study permitted us to conclude that the high level of T 4 found in the CSF, CP, ER, and other brain regions may reflect the presence of TTR in the CSF compartment. In its turn, TTR may represent a major contributing factor in keeping high concentration of free T 4 in CSF, as well as brain. In addition, both brain barriers may also play an essential role in the homeostasis of CNS T 4 . Carriermediated and RME may represent a mode for T 4 transfer from the CSF into brain regions. These studies provide new insight into T 4 transport systems within the CNS and form the basis for further investigations to elucidate the importance of these factors and the molecular mechanisms that control the biology of thyroid hormone transport and its delivery into the brain.
